Previous 10 | Next 10 |
Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in Europe with Proposed Pricing of approximately €200 per Month New CEO, Karim Mikhail, to Host Conference Call Today at 7:30 a.m. ET ...
3 Penny Stocks For Your Watchlist in Late 2021 With August breezing by, which penny stocks are investors watching right now? Well, to understand this and to make the best penny stocks watchlist , there are a few things to consider. Right now, we are coming to the end of earnings sea...
Amarin Corporation plc is a global pharmaceutical company focused internationally on commercializing its sole therapeutic, Vascepa. Amarin's sole product is Vascepa, an icosapent ethyl-based cardiovascular therapeutic approved by the FDA, EMA, and various other government agencie...
Biopharmaceutical company Lexicon Pharmaceuticals (NASDAQ:LXRX) has appointed Craig Granowitz as Senior Vice President and Chief Medical Officer, effective August 2, 2021. Granowitz was previously Chief Medical Officer at Amarin (NASDAQ:AMRN). In the new role, Granowitz will oversee the ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. It was the fifth consecutive quarter of gains for small c...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. It was the fifth consecutive quarter of gains for small c...
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter and six month 2021 financial results and provide...
A lower court ruling voiding Amarin’s patents was upheld by a court of appeals and the US Supreme Court declined to take up the matter. With one approved drug and a value chain built on differentiation that is facing US market erosion from generics, Amarin would not seem an ent...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Amarin stock surpassed the 75% upside price target in Feb., only to fall from there. Unfavorable Patent ruling expected. Renewed upside for AMRN stock discussed. For further details see: Why Amarin Stock May Rise From Here
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...